Skip to main content
Premium Trial:

Request an Annual Quote

My Gene Counsel, Genomet Develop Decision Support Solution for Precision Cancer Care

NEW YORK – Digital health company My Gene Counsel on Tuesday said it is partnering with Genomet to improve precision cancer care by providing a digital decision support solution for clinicians that combines My Gene Counsel's genetic counseling reports and Genomet's virtual tumor board platform.

The combined My Gene Counsel-Genomet solution will allow health systems, regardless of location, to make full use of cancer patients' somatic and germline genetic test results through real-time input from genetic counselors and tumor board experts, who can also help direct patients to the right drugs and trials based on their molecular information.

Patients and doctors will also have access to the latest information on hereditary cancer test results and medical management, and be notified when new information emerges that may impact care. The joint solution can be implemented quickly, according to the partners, and doesn't require EMR integration.

"Few health systems have the resources or expertise to handle the increased demand and complexity of somatic and germline testing, especially when performed together or when somatic testing indicates potential germline findings," My Gene Counsel CEO Ellen Matloff said in a statement. "Oncologists and patients need point-of-care expertise in this ever-changing, active, and vital field. Together, My Gene Counsel and Genomet will help providers deliver patient-centered care using informatics and data, allowing clinicians everywhere to personalize therapeutics and care for their patients around the globe."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.